共 113 条
[11]
Hashmi SK(2016)Myeloid neoplasms after chemotherapy and PRRT: myth and reality Endocr Relat Cancer 23 C1-C7
[12]
Bhatia S(2019)Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 46 704-717
[13]
McNerney ME(2015)Severe hematological complications associated with peptide receptor radionuclide therapy: 15 years of experience at Bad Berka World J Nucl Med 14 2-117
[14]
Godley LA(2014)Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up Neuroendocrinology. 99 108-L23
[15]
Le Beau MM(2016)High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy Endocr Relat Cancer 23 L17-2088
[16]
Larson RA(1997)International scoring system for evaluating prognosis in myelodysplastic syndromes Blood. 89 2079-2465
[17]
Kesavan M(2012)Revised international prognostic scoring system for myelodysplastic syndromes Blood. 120 2454-12
[18]
Turner JH(2017)Secondary myeloid neoplasms: bone marrow cytogenetic and histological features may be relevant to prognosis Rev Bras Hematol Hemoter 39 4-5915
[19]
Baum RP(2018)Therapy-related myeloid neoplasms: clinical perspectives Onco Targets Ther 11 5909-410
[20]
Kulkarni HR(2014)A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia Clin Lymphoma Myeloma Leuk 14 401-280